I have been, for some time, the recipient of many messages from people directly or indirectly affected by this bacterium. It appears that its rare disease status, which is inherent in the 2006 consensus, prevents patients from receiving optimal access to care. According to the applicants, the detection of the disease in some countries is organised in such a way as to raise only a marginal number of positive tests, the outcome of which is also not always certain by the medical world. They therefore ask for the recognition of Lyme disease as a chronic as well as the homologation of the veterinary test called polymerase Chain reaction (PCR), the only reliable test for disease detection by directly detecting the DNA of the bacterium. This non-recognition obliges the citizens of certain countries to travel abroad in order to be treated, causing significant costs.
Does the Commission intend to launch a broad consultation on this seemingly anonymous public health issue?